AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

AngioDynamics, Inc. (ANGO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 15, 2026

3 MedTech Stocks Benefiting From Favorable Product Mix Shifts

ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.

Zacks Investment Research • Jan 13, 2026

Down 25.0% in 4 Weeks, Here's Why You Should You Buy the Dip in AngioDynamics (ANGO)

AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Zacks Investment Research • Jan 12, 2026

ANGO Stock Dips Despite Q2 Earnings Beat, Gross Margin Improves

AngioDynamics reports flat Q2 earnings while revenue increase 8.8% and gross margin expands 170 bps on stronger Med Tech performance.

Zacks Investment Research • Jan 7, 2026

Why AngioDynamics Stock Is Sinking Today

The medical technology company announced the retirement of CEO Jim Clemmer. This news creates uncertainty for AngioDynamics -- and investors dislike uncertainty.

The Motley Fool • Jan 6, 2026

AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript

AngioDynamics, Inc. (ANGO) Q2 2026 Earnings Call Transcript

Seeking Alpha • Jan 6, 2026

AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability

LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the second quarter of fiscal year 2026, which ended November 30, 2025. Fiscal Year 2026 Second Quarter Highlights     Quarter Ended November 30, 2025   Pro Forma* YoY Growth Net Sales   $.

Business Wire • Jan 6, 2026

AngioDynamics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

AngioDynamics, Inc. (NASDAQ: ANGO) will release earnings results for its second quarter before the opening bell on Tuesday, Jan. 6, 2026.

Benzinga • Dec 30, 2025

AngioDynamics: Growth Remains Under The Radar

AngioDynamics looks undervalued, with Med Tech segment growth in thrombus management, atherectomy, and NanoKnife driving the investment thesis. Consistent execution on revenue growth and margin improvement, especially in Med Tech, is critical for rerating; legacy Med Device business remains a headwind to sentiment. Recent clinical data for AlphaVac and NanoKnife support further adoption, while Auryon continues steady share gains in a competitive atherectomy market.

Seeking Alpha • Dec 29, 2025

Reasons to Hold AngioDynamics Stock in Your Portfolio for Now

ANGO benefits from NanoKnife, clinical milestones and a balanced portfolio despite tariff headwinds.

Zacks Investment Research • Dec 24, 2025